




RealRate

PHARMACEUTICAL 2016

Paratek Pharmaceuticals Inc
Rank 157 of 295



The relative strengths and weaknesses of Paratek Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Paratek Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 9.8% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	142,417
Cost of Goods Sold	0
Intangible Assets	2,178
Liabilities, Current	20,502
Liabilities, Non-Current	23,176
Other Assets	544
Other Compr. Net Income	0
Other Expenses	-700
Other Liabilities	1,000
Other Net Income	-807
Other Revenues	0
Property and Equipment	779
Research and Development	50,765
Selling, General and Administrative Expense	19,988

Output Variable	Value in 1000 USD
Assets	145,918
Liabilities	44,678
Expenses	70,053
Revenues	0
Stockholders Equity	101,240
Net Income	-70,860
Comprehensive Net Income	-70,860
BaseVar	130,728
ECR before Limited Liability	157%
Economic Capital Ratio	273%